This inventor holds 1 USPTO granted patent. Top assignee: University of California. Active years: 2000.
Company Filing History:
Years Active: 2000
Title: Hsien C Shih: Innovator in Tubulin-Binding Compounds
Introduction
Hsien C Shih is a notable inventor based in San Diego, CA. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target malignant cells. His innovative work has the potential to revolutionize cancer treatment.
Latest Patents
Hsien C Shih holds a patent for "Inadone and tetralone compounds for inhibiting cell proliferation." This patent describes a new family of inadone and tetralone tubulin-binding compounds (TBs). Unlike classical TBs, which inhibit mitosis among affected dividing cells, the TBs of this invention possess two unique properties. First, they induce apoptosis among stationary phase (non-dividing) malignant cells without impairing the viability of normal nonproliferating cells. Second, they affect cells that have acquired multidrug resistance (MDR) more powerfully than they affect cells without MDR. This innovation provides a means to target malignant cells for chemotherapy, even after previous therapies have failed, without affecting normal cells and tissues in the host.
Career Highlights
Hsien C Shih is affiliated with the University of California, where he continues to advance his research in cancer therapeutics. His work has garnered attention for its potential to improve treatment outcomes for patients with resistant forms of cancer.
Collaborations
Hsien C Shih has collaborated with esteemed colleagues, including Dennis A Carson and Howard B Cottam. These partnerships have contributed to the depth and impact of his research.
Conclusion
Hsien C Shih's innovative work in developing targeted cancer therapies showcases his commitment to advancing medical science. His contributions have the potential to significantly improve the lives of patients battling cancer.